GLP-1
Tirzepatide Cost in 2026: Compounded, Zepbound, Mounjaro, Coupons, Insurance
Tirzepatide cost in October 2026: Zepbound self-pay at $299 to $449 a month, list prices near $1,086 and $1,112, Lilly's savings cards and their caps, compounded prices, insurance, Medicare's $50 Bridge copay, HSA rules and a full year worked out.
Published October 12, 2026 · Updated October 18, 2026 · 11 min read
Key takeaways
- The cheapest FDA-approved tirzepatide for cash buyers is Zepbound in a KwikPen or vials through Lilly's self-pay program: $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 to 15 mg when refilled within 45 days, or $499 to $699 if a refill is late.
- List prices are about $1,086 a month for Zepbound and $1,112 for Mounjaro. Mounjaro has no cash program; its savings card brings a covered prescription to as little as $25, with savings capped at $150 a month.
- Compounded tirzepatide costs $180 to $300 a month in most programs, but since the shortage ended in December 2024 it is legal only for a documented individual clinical need.
- Over a year on 10 mg, Zepbound self-pay costs about $5,640 and a typical compounded program about $3,250; on Medicare's GLP-1 Bridge, an eligible patient pays $50 a fill for the KwikPen.
- Every Lilly card excludes Medicare, Medicaid and other government coverage, and the current card terms end December 31, 2026. Prescribed tirzepatide generally qualifies for HSA and FSA funds.
Tirzepatide cost in October 2026 depends less on the drug than on how you pay for it. The same molecule costs about $1,100 a month at list price as Zepbound or Mounjaro, $299 to $449 as Zepbound bought for cash through Lilly, $180 to $300 as a compounded vial, and $25 to $50 for people whose insurance or Medicare coverage applies. This page sets out each price with its conditions, the coupons and their limits, and what a full year costs. If you only want the lowest legitimate price for your situation, our cheapest tirzepatide guide ranks the options; if you shop at a warehouse club, see what Zepbound costs at Costco. All three use the figures in our peptide therapy cost guide, plus Lilly's own terms read on October 18, 2026.
Tirzepatide cost by option, October 2026
| Option | Monthly price | Conditions | Who can use it |
|---|---|---|---|
| Zepbound KwikPen or vials, Lilly self-pay | $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) with a refill within 45 days; $499 (7.5 mg) and $699 (10 to 15 mg) otherwise | One KwikPen or four vials per 28 days; your own prescription | Cash buyers, including the commercially insured without Zepbound coverage; no government beneficiaries |
| Zepbound on TrumpRx | Average of $346 | A listing of the manufacturer's cash price; no prescriber | Cash, with a prescription |
| Zepbound single-dose pen, list | About $1,086 | Four autoinjector pens | The price insurers start from |
| Zepbound pen with savings card, covered | As little as $25 for up to three months | Savings capped at $100 a month, $1,300 a year | Commercial plans that cover Zepbound |
| Zepbound pen with savings card, not covered | As low as $499 | Commercial insurance that excludes Zepbound | Commercially insured only |
| Mounjaro, list | About $1,112 (January 2026) | Four single-dose pens | Type 2 diabetes label; no cash program |
| Mounjaro with savings card | As little as $25 covered (cap $150 a month); as low as $499 not covered | Card terms end December 31, 2026 | Commercially insured only |
| Medicare GLP-1 Bridge | $50 copay | Zepbound KwikPen only, prior authorization | Part D enrollees meeting BMI criteria |
| Compounded tirzepatide, telehealth | $180 to $300 typical; $99 to $399 range | Usually visit, vial and syringes; some add a membership | Only with a documented individual need |
Sources: Lilly's self-pay and savings-card terms (Lilly Zepbound savings) (Lilly Mounjaro savings); TrumpRx and the Zepbound list price from the federal pricing agreement (White House 2025); Mounjaro's list price from a price tracker (The Rx Index 2026); Medicare from the Bridge notice (UnitedHealthcare 2026). A tracker of 27 compounded programs found continuing prices from $116 to $399, median $249, in checks through October 2026 (Telehealth Ledger).
Zepbound: three devices, three price structures
Zepbound now comes in three forms, and Lilly prices them differently.
Single-dose vials were the first self-pay product, sold through LillyDirect. You draw each weekly dose with a syringe.
The KwikPen, approved February 23, 2026, holds four weekly doses in one multi-dose pen. Lilly launched it at the same self-pay price as the vials, starting at $299 for 2.5 mg, and at first sold it only through LillyDirect (Lilly 2026). On March 13, Kroger announced that its pharmacies would honor Lilly's KwikPen Self-Pay Savings Card, which it described as the first time self-pay patients could use the card at a retail pharmacy (Kroger 2026). Lilly's savings page now offers the card for LillyDirect or another pharmacy. Lilly notes that pen needles are sold separately.
The single-dose autoinjector pen, the original Zepbound, is excluded from the self-pay prices. Lilly states that the $299 price is "for the Zepbound KwikPen or vial, not Zepbound single-dose Pen" (Lilly Zepbound savings). Without coverage, the pen costs near list price, or as low as $499 for commercially insured patients whose plan excludes it.
The refill rule is where cash buyers lose money. The $449 price at 7.5 mg and above holds only if each refill is bought within 45 days of receiving the previous one. A late refill at 10 mg costs $699 for the same pen, $250 more. The 2.5 and 5 mg prices do not change with timing.
Coupons and savings cards, and their limits
Lilly runs separate cards for each situation, and all of them share three rules: they exclude anyone whose prescription is paid by Medicare, Medicaid or another government program; they require a prescription for an approved use; and the current terms end on December 31, 2026 (Lilly Zepbound savings).
| Card | Who it is for | What you pay | Cap |
|---|---|---|---|
| Zepbound KwikPen Self-Pay Savings Card | No insurance, or insurance you are not using | $299 to $449 a month by dose | Price set by dose and refill timing |
| Zepbound Savings Card, covered | Commercial plan covers the single-dose pen | As little as $25 for a 1- to 3-month fill | $100 a month, $1,300 a year |
| Zepbound Savings Card, not covered | Commercial plan excludes Zepbound | As low as $499 a month | Up to 13 fills a year |
| Mounjaro Savings Card, covered | Commercial plan covers Mounjaro | As little as $25 for a 1- to 3-month fill | $150 a month, $1,950 a year |
| Mounjaro Savings Card, not covered | Commercial plan excludes Mounjaro | As low as $499 a month | $647 a month |
The caps decide whether "$25" is what you pay. If your plan's copay for Zepbound is $75, the card covers $50 and you pay $25. If your plan leaves you with a $300 coinsurance bill, the card covers $100 and you pay $200 (Lilly Zepbound savings). Mounjaro's higher cap of $150 a month covers more of a high copay (Lilly Mounjaro savings).
Pharmacy discount cards, the kind printed by price-comparison sites, are a different product: they lower a pharmacy's own cash price and are not Lilly programs. Ask the pharmacist to price your fill both ways and take the lower.
The first three months, worked out
The label starts at 2.5 mg weekly for four weeks, then 5 mg, then increases of 2.5 mg no sooner than every four weeks; the full schedule is in the tirzepatide dosage chart. Assuming four-week fills and increases at the earliest interval:
| Route | Month 1 (2.5 mg) | Month 2 (5 mg) | Month 3 (7.5 mg) | Three months |
|---|---|---|---|---|
| Zepbound self-pay, refills on time | $299 | $399 | $449 | $1,147 |
| Zepbound self-pay, third refill late | $299 | $399 | $499 | $1,197 |
| Zepbound pen at list | $1,086 | $1,086 | $1,086 | $3,258 |
| Mounjaro at list | $1,112 | $1,112 | $1,112 | $3,336 |
| Medicare Bridge, if eligible | $50 | $50 | $50 | $150 |
| Compounded, typical program | $180 to $300 | $180 to $300 | $180 to $300 | $540 to $900 |
Add the program costs: a first consultation of $0 to $200, baseline labs of $100 to $400 if ordered, and any membership. A telehealth service that writes a Zepbound prescription usually charges its own visit or membership fee on top of Lilly's price, while a compounded program usually bundles the visit.
A full year, and why the year is the number to compare
Tirzepatide is a long-term drug. In SURMOUNT-4, 670 adults who lost 20.9% of their weight over 36 weeks on tirzepatide were randomized to continue or switch to placebo; over the next 52 weeks the placebo group regained 14.0% while the tirzepatide group lost a further 5.5% (Aronne 2024). A one-month price tells you little.
| Route, 13 four-week fills | Maintenance at 5 mg | Maintenance at 10 mg |
|---|---|---|
| Zepbound self-pay, refills on time | About $5,090 | About $5,640 |
| Zepbound self-pay, every refill late from 7.5 mg | About $5,090 | About $8,190 |
| Compounded at $250 a month | About $3,250 | About $3,250 (often more at higher doses) |
| Medicare Bridge at $50 | $650 | $650 |
The 10 mg row is $299 + $399 + 11 × $449; the late row uses $499 at 7.5 mg and $699 after. Many compounded programs charge more as the dose rises, with 10 to 15 mg commonly priced at $280 to $385, so the compounded discount narrows at maintenance.
Dose also matters for price. In SURMOUNT-1, 2,539 adults with obesity and without diabetes lost an average of 15.0% of their weight over 72 weeks at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% on placebo (Jastreboff 2022). On the self-pay schedule, 5 mg costs $399 and every higher dose $449, so the higher doses add $50 a month. The choice of dose belongs to you and your prescriber, on efficacy and side effects; cost is a minor factor at these prices.
Insurance, Medicare and HSA
Commercial insurance. Mounjaro is widely covered for type 2 diabetes. Zepbound is covered for obesity by some commercial plans, usually with prior authorization and a BMI threshold. In May 2026, Lilly said all three of the largest pharmacy benefit managers would cover its obesity medicines, with CVS Caremark's template plans broadening Zepbound coverage by October 1, 2026 (Lilly 2026b). Whether your employer's plan opts in is a separate question; check before paying cash. Self-pay prices cannot be combined with insurance, and compounded tirzepatide is cash only.
Medicare. Part D has long been barred from covering drugs for weight loss. The November 2025 agreement between the federal government and the manufacturers set a $245 Medicare price and a $50 copay (White House 2025). The first piece arrived on July 1, 2026 as the Medicare GLP-1 Bridge, a temporary demonstration run outside Part D plans by a CMS contractor. It covers the Zepbound KwikPen but not vials or the single-dose pen, along with Wegovy and Foundayo, and excludes Mounjaro (UnitedHealthcare 2026). Eligibility under CMS's criteria: a BMI of 35 or more; 30 or more with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or worse kidney disease; or 27 or more with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. People prescribed Zepbound for a use Part D already covers, such as sleep apnea in adults with obesity, go through their plan instead (Reed Smith 2026). The prescriber should mark the prescription for the Bridge, or the pharmacy may bill your plan, which will usually deny it.
HSA and FSA. IRS Publication 502 counts prescribed medicines as medical expenses and allows weight-loss costs when they treat a specific disease diagnosed by a physician, such as obesity (IRS Publication 502). That covers brand and compounded tirzepatide on a prescription and the visits to get it. Paying with pre-tax money lowers the effective price by your income-tax rate: in the 22% federal bracket, a $449 fill costs about $350 in after-tax dollars. Supplements and anything bought without a prescription do not qualify.
Compounded tirzepatide: what the lower price buys
Compounded tirzepatide is made by a pharmacy from bulk ingredient, typically in a multi-dose vial. It is not FDA-approved and FDA does not test it. FDA declared the tirzepatide shortage resolved on December 19, 2024, and since the grace periods ended in 2025, a 503A pharmacy may compound it only for a patient whose documented clinical need the approved product cannot meet; price alone is not such a need. FDA sent 55 warning letters to telehealth companies over compounded GLP-1 marketing in 2026, and on September 18 warned Empower Pharmacy that adding an ingredient such as niacinamide does not create a legal basis. The details are in our legal explainer and the regulatory tracker, and the product itself in the compounded tirzepatide hub.
At $180 to $300 a month, a compounded program saves roughly $1,700 to $3,300 a year against Zepbound self-pay at maintenance. That saving is real; so is the legal requirement attached to it. If you have such a need, ask which licensed 503A pharmacy fills the prescription and check it yourself.
Which route costs least for you
- Type 2 diabetes with commercial coverage: Mounjaro through your plan, with the savings card.
- Obesity with a plan that covers Zepbound: prior authorization through your clinician, then the savings card.
- Medicare, BMI criteria met: the Bridge at $50 for the KwikPen.
- Paying cash: the Zepbound KwikPen or vials at $299 to $449, refilled within 45 days, with a prescription from your own clinician or a telehealth visit.
- A documented reason the brand will not work for you: a compounded product from a named, licensed 503A pharmacy.
The cheapest tirzepatide guide works through each of these with the catches. To compare programs that quote different vial sizes and fees, run the numbers in the peptide price calculator, and use the peptide calculator to turn a prescribed compounded dose into syringe units. Providers that prescribe brand and compounded tirzepatide are compared in our online clinic directory.
Red flags on a tirzepatide price
- A $99 first month. Read the price at months two to four; dose-based pricing commonly reaches $280 to $385 at 10 to 15 mg.
- A price for a dose below 2.5 mg. The label's lowest dose is a starting dose, not a maintenance dose; a cheap 'microdose' plan buys less drug.
- A membership on top of the medication, or a cancellation fee hidden in a 12-month plan.
- 'Generic Zepbound' or 'same as Mounjaro'. There is no generic tirzepatide; FDA's 2026 warning letters quoted claims like these.
- 'Research use only' vials at a fraction of pharmacy prices: unapproved drugs sold without a prescription, which FDA warned sellers about in March and August 2026.
- No pharmacy named before you pay.
Bottom line
Tirzepatide costs about $1,100 a month at list, but few people should pay that. Cash buyers can get Zepbound for $299 to $449 through Lilly's program, insured patients can get to $25 within the card's caps, and eligible Medicare enrollees pay $50 for the KwikPen. Compounded tirzepatide costs less again, by a few thousand dollars a year, and is lawful only with a documented clinical need. Price the year, refill on time, and check whether your plan now covers Zepbound before you pay cash.
Frequently asked questions
+How much is tirzepatide?
In October 2026, a month of brand Zepbound costs $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 to 15 mg through Lilly's self-pay program when you refill within 45 days, and about $1,086 at list price. Mounjaro lists at about $1,112. Compounded tirzepatide usually costs $180 to $300 a month. With insurance or Medicare, eligible patients can pay $25 to $50.
+What is the cost of tirzepatide without insurance?
The lowest FDA-approved cash price is Zepbound in a KwikPen or vials through Lilly's self-pay program: $299 to $449 a month by dose with on-time refills, and $499 to $699 at 7.5 mg and above if a refill is late. Mounjaro has no comparable cash program and costs about $1,100 a month at list.
+How much does compounded tirzepatide cost?
Most telehealth programs charge $180 to $300 a month, with a range of about $99 to $399. A tracker of 27 programs found continuing prices from $116 to $399, median $249, in September and October 2026. The lowest prices need 6- or 12-month commitments, and since the shortage ended a compounded version is legal only for a documented individual clinical need.
+Is there a coupon for tirzepatide?
Lilly runs three. The Zepbound KwikPen self-pay card sets the $299 to $449 cash prices. The Zepbound and Mounjaro savings cards bring a covered prescription to as little as $25, but cap the savings at $100 a month for Zepbound and $150 for Mounjaro. Commercially insured patients without coverage can pay as low as $499 for the pens. All cards exclude Medicare, Medicaid and other government plans, and the current terms end December 31, 2026.
+Is Zepbound cheaper than Mounjaro?
For cash buyers, yes. Both contain tirzepatide at the same doses, but Zepbound has a self-pay price of $299 to $449 a month while Mounjaro costs about $1,100 at list. With commercial insurance that covers it, Mounjaro can cost $25 with Lilly's card, which is why people with type 2 diabetes usually go through their plan.
+Does insurance cover tirzepatide?
Mounjaro is widely covered for type 2 diabetes. Zepbound is covered for obesity by some commercial plans, usually with prior authorization and a BMI threshold, and Lilly says all three of the largest pharmacy benefit managers now cover it, with CVS Caremark template plans restored by October 1, 2026. Its sleep-apnea use can be covered under Medicare Part D. Compounded tirzepatide is cash only.
+Does Medicare cover Zepbound?
For sleep apnea in adults with obesity, a Part D plan can cover it. For weight management, the temporary Medicare GLP-1 Bridge, running since July 1, 2026, covers the Zepbound KwikPen (not vials or single-dose pens) at a $50 monthly copay for Part D enrollees who meet BMI criteria, through prior authorization handled by a CMS contractor.
+Can I use my HSA or FSA for tirzepatide?
Generally yes, for a prescribed drug and the clinician visits to get it; IRS Publication 502 counts prescribed medicines and treatment of a diagnosed disease such as obesity as medical expenses. Supplements and anything bought without a prescription do not qualify. Keep the prescription and an itemized receipt.
Sources
- SourceEli Lilly. Zepbound savings and insurance options: KwikPen Self-Pay Savings Card and Zepbound Savings Card terms and conditions (read October 18, 2026). (2026)
- SourceEli Lilly. Mounjaro savings and coverage: savings card terms and conditions (read October 18, 2026). (2026)
- NewsEli Lilly. Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen. Press release, February 23, 2026. (2026)
- NewsEli Lilly. Foundayo and Zepbound now covered for millions of Americans (CVS Caremark resumes Zepbound coverage by October 1). Press release, May 28, 2026. (2026)
- NewsThe Kroger Co. Kroger brings Zepbound KwikPen to retail pharmacy, expanding access and savings for self-pay patients. Press release, March 13, 2026. (2026)
- RegulatoryThe White House. Fact sheet: most-favored-nation pricing agreements with Novo Nordisk and Eli Lilly (Zepbound from $1,086 to an average of $346 on TrumpRx; $245 Medicare price and $50 copay). November 6, 2025. (2025)
- SourceThe Rx Index. Mounjaro without insurance 2026: list price $1,112.16 as of January 2026 (affiliate site). (2026)
- SourceUnitedHealthcare. Medicare GLP-1 Bridge program: what you need to know (covered drugs, eligibility, prior authorization). Provider notice, August 11, 2026. (2026)
- NewsReed Smith. CMS provides details for Medicare GLP-1 Bridge coverage for eligible Part D beneficiaries (CMS FAQ of March 3, 2026). March 9, 2026. (2026)
- SourceTelehealth Ledger. Compounded tirzepatide prices: 27 programs publishing continuing prices from $116 to $399 a month, median $249 (price tracker with affiliate links; checked September to October 2026). (2026)
- RegulatoryIRS. Publication 502 (2025), Medical and Dental Expenses: prescribed medicines and drugs; weight-loss program. (2025)
- StudyJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. (2022)
- StudyAronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. (2024)
Written by
The Peptide Doctrine Editorial Team
Our editors write from primary sources — peer-reviewed studies, FDA documents and pharmacy records — and grade every claim by the strength of its evidence. See our editorial policy for how articles are researched, reviewed and updated.
Disclosure. The Peptide Doctrine is an independent editorial project. It currently has no sponsor and runs no advertising: we accept no payment for reviews, rankings or placements, we run no affiliate links, and we do not sell or link to "research-use" peptide vendors. Content is educational and is not medical advice.
Related
GLP-1
Compounded Tirzepatide: What It Is, Who Can Prescribe It, Dosing, Cost and 2026 Legal Status
Compounded tirzepatide explained: how it differs from Mounjaro and Zepbound, who can legally prescribe it in 2026, the label dosing schedule and how vial doses convert to syringe units, what it costs against brand vials, the risks specific to compounded copies, and how to spot an illegal copy.
Updated Oct 12, 2026 · 16 min read
GLP-1
Is Compounded Tirzepatide Still Legal in 2026? FDA Shortage Rules, 503A/503B, What Changed
Is compounded tirzepatide still available in 2026? Only in a narrow lane. The legal timeline from the 2022 shortage to the 2026 warning letters and the Fifth Circuit ruling, what 503A and 503B allow, what is legal now and how to tell what you are offered.
Updated Oct 12, 2026 · 13 min read
GLP-1
Tirzepatide Online: How to Get It Prescribed Legitimately
Tirzepatide online, legitimately: the lawful routes in 2026 (a clinician licensed in your state, Zepbound through Lilly's self-pay program or TrumpRx, Mounjaro for diabetes, compounded only for documented need), what a telehealth visit involves, how to check licenses and the research-vial trap.
Updated Oct 12, 2026 · 7 min read
GLP-1
Zepbound vs Wegovy: Weight Loss Data, Side Effects, Cost, Compounded Equivalents
Zepbound vs Wegovy in October 2026: the head-to-head trial (20.2% vs 13.7% weight loss), what each label covers (heart, liver, sleep apnea), label side-effect rates, doses and devices, cash prices, Medicare, the pills, and where compounded versions stand.
Updated Oct 12, 2026 · 13 min read